IDENTIFICATION OF SERUM PROTEOMIC PROFILE IN CANINE LYMPHOMAS

Abstract

Lymphoma is the third most commonly diagnosed, malignant hematopoietic tumor in dogs, and it is similar to human non-Hodgkin's lymphoma. Proteomics refer to the large-scale study of proteins, including their structures as well as their complex protein mixtures. It also involves identifying the changes in the protein isoforms and posttranslational modifications expressed by genetic material under defined specific conditions. This study was aimed at identifying the serum proteomic profiles of canine lymphoma compared with healthy dogs by using Tandem Mass Tag (TMT). Blood samples from twenty lymphoma and four healthy dogs were collected. All cases were categorized according to the WHO clinical stage, confirmed either by cytological and heteroduplex polymerase chain reaction (hPAAR) or histopathological and immunophenotyping to determine B-cell or T-cell lymphoma, then serum proteomics were performed by liquid chromatography mass spectrometry (LC-MS/MS). Thirty-four individual proteins were identified from C. lupus familiaris. Six proteins were significantly different between control and lymphoma groups. Albumin was significantly decreasing, while five proteins were significantly increasing in lymphoma group such as clusterin or apolipoprotein J, Ig heavy chain V region GOM, beta-2-microglobulin, apolipoprotein C-I, and haptoglobin. This technique is able to detect low abundance proteins with a high degree of statistical confidence. These protein panels may be the possible candidate biomarkers for canine lymphoma in clinical oncology for the future.